D-0165-2025 Class II Ongoing
FDA drug recall D-0165-2025 was initiated by RemedyRepack Inc. on Dec 2, 2024 and is designated Class II. Reason for recall: CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit. The recall status is ongoing. Affected quantity: a) 1,564 cards, b) 799 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 1, 2025
- Initiation Date
- Dec 2, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- a) 1,564 cards, b) 799 bottles
Product description
Duloxetine Delayed-Release Capsules, 60 mg, a) 30 count blister cards (NDC 70518-0937-04), b) 30 count bottles (NDC 70518-0937-03), Rx only, Source NDC 57237-0019-99, MFG: Rising Pharma, Inc., Allendale, NJ, Repackaged by: RemedyRepack Inc., Indiana, PA
Reason for recall
CGMP Deviations; presence of N-nitroso-duloxetine impurity above recommended interim limit.
Distribution pattern
Nationwide in the US
Code information
a) NDC 70518-0937-04, Lot # J0786744-061724, Exp. 06/30/2025 b) NDC 70518-0937-03, Lot # B3002625-060524, Exp. 10/31/2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0165-2025
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026